Home > > > > Report Detail

Global Antisense and RNAi Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 15-Sep-2022
No. of pages: 98
Inquire Before Buying

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Antisense and RNAi Therapeutics companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Antisense and RNAi Therapeutics market. Further, it explains the major drivers and regional dynamics of the global Antisense and RNAi Therapeutics market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Tekmira Pharmaceuticals

- Arbutus Biopharma

- Alnylam Pharmaceuticals

- Antisense Therapeutics

- Silence Therapeutics

- Isis Pharmaceuticals

- Sirnaomics

- Santaris

- Roche

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Antisense and RNAi Therapeutics Segment by Type

- RNA Interference

- Antisense RNA

Antisense and RNAi Therapeutics Segment by Application

- Hospital

- Clinic

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Antisense and RNAi Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Antisense and RNAi Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Antisense and RNAi Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antisense and RNAi Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense and RNAi Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Antisense and RNAi Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Antisense and RNAi Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris and Roche, etc.

Global Antisense and RNAi Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 RNA Interference
1.2.3 Antisense RNA
1.3 Market by Application
1.3.1 Global Antisense and RNAi Therapeutics Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Antisense and RNAi Therapeutics Market Size (2017-2028)
2.2 Antisense and RNAi Therapeutics Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Antisense and RNAi Therapeutics Market Size by Region (2017-2022)
2.4 Global Antisense and RNAi Therapeutics Market Size Forecast by Region (2023-2028)
2.5 Global Top Antisense and RNAi Therapeutics Countries Ranking by Market Size
3 Antisense and RNAi Therapeutics Competitive by Company
3.1 Global Antisense and RNAi Therapeutics Revenue by Players
3.1.1 Global Antisense and RNAi Therapeutics Revenue by Players (2017-2022)
3.1.2 Global Antisense and RNAi Therapeutics Market Share by Players (2017-2022)
3.2 Global Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Antisense and RNAi Therapeutics Revenue
3.4 Global Antisense and RNAi Therapeutics Market Concentration Ratio
3.4.1 Global Antisense and RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense and RNAi Therapeutics Revenue in 2021
3.5 Global Antisense and RNAi Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense and RNAi Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense and RNAi Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Antisense and RNAi Therapeutics Breakdown Data by Type
4.1 Global Antisense and RNAi Therapeutics Historic Revenue by Type (2017-2022)
4.2 Global Antisense and RNAi Therapeutics Forecasted Revenue by Type (2023-2028)
5 Global Antisense and RNAi Therapeutics Breakdown Data by Application
5.1 Global Antisense and RNAi Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antisense and RNAi Therapeutics Revenue by Company (2020-2022)
6.2 North America Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
6.3 North America Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
6.4 North America Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Antisense and RNAi Therapeutics Revenue by Company (2020-2022)
7.2 Europe Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
7.3 Europe Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
7.4 Europe Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Antisense and RNAi Therapeutics Revenue by Company (2020-2022)
8.2 Asia Pacific Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
8.3 Asia Pacific Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
8.4 Asia Pacific Antisense and RNAi Therapeutics Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Antisense and RNAi Therapeutics Revenue by Company (2020-2022)
9.2 Latin America Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
9.3 Latin America Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
9.4 Latin America Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Antisense and RNAi Therapeutics Revenue by Company (2020-2022)
10.2 Middle East and Africa Antisense and RNAi Therapeutics Revenue by Type (2017-2028)
10.3 Middle East and Africa Antisense and RNAi Therapeutics Revenue by Application (2017-2028)
10.4 Middle East and Africa Antisense and RNAi Therapeutics Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Tekmira Pharmaceuticals
11.1.1 Tekmira Pharmaceuticals Company Details
11.1.2 Tekmira Pharmaceuticals Business Overview
11.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Products and Services
11.1.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.1.5 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
11.1.6 Tekmira Pharmaceuticals Recent Developments
11.2 Arbutus Biopharma
11.2.1 Arbutus Biopharma Company Details
11.2.2 Arbutus Biopharma Business Overview
11.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Products and Services
11.2.4 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.2.5 Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
11.2.6 Arbutus Biopharma Recent Developments
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Details
11.3.2 Alnylam Pharmaceuticals Business Overview
11.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Products and Services
11.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.3.5 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
11.3.6 Alnylam Pharmaceuticals Recent Developments
11.4 Antisense Therapeutics
11.4.1 Antisense Therapeutics Company Details
11.4.2 Antisense Therapeutics Business Overview
11.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Products and Services
11.4.4 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.4.5 Antisense Therapeutics Antisense and RNAi Therapeutics SWOT Analysis
11.4.6 Antisense Therapeutics Recent Developments
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Details
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Products and Services
11.5.4 Silence Therapeutics Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.5.5 Silence Therapeutics Antisense and RNAi Therapeutics SWOT Analysis
11.5.6 Silence Therapeutics Recent Developments
11.6 Isis Pharmaceuticals
11.6.1 Isis Pharmaceuticals Company Details
11.6.2 Isis Pharmaceuticals Business Overview
11.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Products and Services
11.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.6.5 Isis Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
11.6.6 Isis Pharmaceuticals Recent Developments
11.7 Sirnaomics
11.7.1 Sirnaomics Company Details
11.7.2 Sirnaomics Business Overview
11.7.3 Sirnaomics Antisense and RNAi Therapeutics Products and Services
11.7.4 Sirnaomics Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.7.5 Sirnaomics Antisense and RNAi Therapeutics SWOT Analysis
11.7.6 Sirnaomics Recent Developments
11.8 Santaris
11.8.1 Santaris Company Details
11.8.2 Santaris Business Overview
11.8.3 Santaris Antisense and RNAi Therapeutics Products and Services
11.8.4 Santaris Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.8.5 Santaris Antisense and RNAi Therapeutics SWOT Analysis
11.8.6 Santaris Recent Developments
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Antisense and RNAi Therapeutics Products and Services
11.9.4 Roche Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022)
11.9.5 Roche Antisense and RNAi Therapeutics SWOT Analysis
11.9.6 Roche Recent Developments
12 Antisense and RNAi Therapeutics Market Dynamics
12.1 Antisense and RNAi Therapeutics Market Trends
12.2 Antisense and RNAi Therapeutics Market Drivers
12.3 Antisense and RNAi Therapeutics Market Challenges
12.4 Antisense and RNAi Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
Table 1. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of RNA Interference
Table 3. Key Players of Antisense RNA
Table 4. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Antisense and RNAi Therapeutics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 6. Global Antisense and RNAi Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 7. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2017-2022)
Table 8. Global Antisense and RNAi Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 9. Global Antisense and RNAi Therapeutics Market Share by Players (2017-2022)
Table 10. Global Top Antisense and RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2021)
Table 11. Ranking of Global Top Antisense and RNAi Therapeutics Companies by Revenue (US$ Million) in 2021
Table 12. Global 5 Largest Players Market Share by Antisense and RNAi Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 13. Key Players Headquarters and Area Served
Table 14. Key Players Antisense and RNAi Therapeutics Product Solution and Service
Table 15. Date of Key Manufacturers Enter into Antisense and RNAi Therapeutics Market
Table 16. Mergers & Acquisitions, Expansion Plans
Table 17. Global Antisense and RNAi Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 18. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2017-2022)
Table 19. Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 20. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2023-2028)
Table 21. Global Antisense and RNAi Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 22. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2022)
Table 23. Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 24. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2023-2028)
Table 25. North America Antisense and RNAi Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 26. North America Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 27. North America Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 28. North America Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 29. North America Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 30. North America Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 31. North America Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 32. Europe Antisense and RNAi Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 33. Europe Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 34. Europe Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 35. Europe Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 36. Europe Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 37. Europe Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 38. Europe Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 39. Asia Pacific Antisense and RNAi Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 40. Asia Pacific Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 41. Asia Pacific Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 42. Asia Pacific Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 43. Asia Pacific Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 44. Asia Pacific Antisense and RNAi Therapeutics Revenue by Region (2017-2022) & (US$ Million)
Table 45. Asia Pacific Antisense and RNAi Therapeutics Revenue by Region (2023-2028) & (US$ Million)
Table 46. Latin America Antisense and RNAi Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 47. Latin America Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 48. Latin America Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 49. Latin America Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 50. Latin America Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 51. Latin America Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 52. Latin America Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 53. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Company (2020-2022) & (US$ Million)
Table 54. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Type (2017-2022) & (US$ Million)
Table 55. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Type (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Application (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Application (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Country (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Antisense and RNAi Therapeutics Revenue by Country (2023-2028) & (US$ Million)
Table 60. Tekmira Pharmaceuticals Company Details
Table 61. Tekmira Pharmaceuticals Business Overview
Table 62. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product and Services
Table 63. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 65. Tekmira Pharmaceuticals Recent Developments
Table 66. Arbutus Biopharma Company Details
Table 67. Arbutus Biopharma Business Overview
Table 68. Arbutus Biopharma Antisense and RNAi Therapeutics Product and Services
Table 69. Arbutus Biopharma Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 70. Arbutus Biopharma Antisense and RNAi Therapeutics SWOT Analysis
Table 71. Arbutus Biopharma Recent Developments
Table 72. Alnylam Pharmaceuticals Company Details
Table 73. Alnylam Pharmaceuticals Business Overview
Table 74. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product and Services
Table 75. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 76. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 77. Alnylam Pharmaceuticals Recent Developments
Table 78. Antisense Therapeutics Company Details
Table 79. Antisense Therapeutics Business Overview
Table 80. Antisense Therapeutics Antisense and RNAi Therapeutics Product and Services
Table 81. Antisense Therapeutics Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 82. Antisense Therapeutics Antisense and RNAi Therapeutics SWOT Analysis
Table 83. Antisense Therapeutics Recent Developments
Table 84. Silence Therapeutics Company Details
Table 85. Silence Therapeutics Business Overview
Table 86. Silence Therapeutics Antisense and RNAi Therapeutics Product and Services
Table 87. Silence Therapeutics Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 88. Silence Therapeutics Antisense and RNAi Therapeutics SWOT Analysis
Table 89. Silence Therapeutics Recent Developments
Table 90. Isis Pharmaceuticals Company Details
Table 91. Isis Pharmaceuticals Business Overview
Table 92. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product and Services
Table 93. Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Isis Pharmaceuticals Antisense and RNAi Therapeutics SWOT Analysis
Table 95. Isis Pharmaceuticals Recent Developments
Table 96. Sirnaomics Company Details
Table 97. Sirnaomics Business Overview
Table 98. Sirnaomics Antisense and RNAi Therapeutics Product and Services
Table 99. Sirnaomics Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 100. Sirnaomics Antisense and RNAi Therapeutics SWOT Analysis
Table 101. Sirnaomics Recent Developments
Table 102. Santaris Company Details
Table 103. Santaris Business Overview
Table 104. Santaris Antisense and RNAi Therapeutics Product and Services
Table 105. Santaris Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 106. Santaris Antisense and RNAi Therapeutics SWOT Analysis
Table 107. Santaris Recent Developments
Table 108. Roche Company Details
Table 109. Roche Business Overview
Table 110. Roche Antisense and RNAi Therapeutics Product and Services
Table 111. Roche Antisense and RNAi Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 112. Roche Antisense and RNAi Therapeutics SWOT Analysis
Table 113. Roche Recent Developments
Table 114. Antisense and RNAi Therapeutics Market Trends
Table 115. Antisense and RNAi Therapeutics Market Drivers
Table 116. Antisense and RNAi Therapeutics Market Challenges
Table 117. Antisense and RNAi Therapeutics Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense and RNAi Therapeutics Sales Market Share by Type: 2021 VS 2028
Figure 2. RNA Interference Features
Figure 3. Antisense RNA Features
Figure 4. Global Antisense and RNAi Therapeutics Sales Market Share by Application: 2021 VS 2028
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Antisense and RNAi Therapeutics Report Years Considered
Figure 8. Global Antisense and RNAi Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Antisense and RNAi Therapeutics Market Size 2017-2028 (US$ Million)
Figure 10. Global Antisense and RNAi Therapeutics Market Size Market Share by Region: 2021 VS 2028
Figure 11. Global Antisense and RNAi Therapeutics Revenue Market Share by Region in 2017 VS 2022
Figure 12. Global Top 10 Antisense and RNAi Therapeutics Countries Ranking by Market Size (US$ Million) in 2021
Figure 13. Global Antisense and RNAi Therapeutics Market Share by Players in 2021
Figure 14. Global Top Antisense and RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Antisense and RNAi Therapeutics Revenue in 2021
Figure 16. North America Antisense and RNAi Therapeutics Revenue Market Share by Company in 2021
Figure 17. North America Antisense and RNAi Therapeutics Revenue Market Share by Type (2017-2028)
Figure 18. North America Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2028)
Figure 19. North America Antisense and RNAi Therapeutics Revenue Share by Country (2017-2028)
Figure 20. U.S. Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 21. Canada Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 22. Europe Antisense and RNAi Therapeutics Revenue Market Share by Company in 2021
Figure 23. Europe Antisense and RNAi Therapeutics Revenue Market Share by Type (2017-2028)
Figure 24. Europe Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2028)
Figure 25. Europe Antisense and RNAi Therapeutics Revenue Share by Country (2017-2028)
Figure 26. Germany Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 27. France Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 28. U.K. Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 29. Italy Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 30. Russia Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 31. Asia Pacific Antisense and RNAi Therapeutics Revenue Market Share by Company in 2021
Figure 32. Asia Pacific Antisense and RNAi Therapeutics Revenue Market Share by Type (2017-2028)
Figure 33. Asia Pacific Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2028)
Figure 34. Asia Pacific Antisense and RNAi Therapeutics Revenue Share by Region (2017-2028)
Figure 35. China Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 36. Japan Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 37. South Korea Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 38. India Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 39. Australia Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 40. Taiwan Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 41. Indonesia Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 42. Thailand Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 43. Malaysia Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 44. Philippines Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 45. Vietnam Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 46. Latin America Antisense and RNAi Therapeutics Revenue Market Share by Company in 2021
Figure 47. Latin America Antisense and RNAi Therapeutics Revenue Market Share by Type (2017-2028)
Figure 48. Latin America Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2028)
Figure 49. Latin America Antisense and RNAi Therapeutics Revenue Share by Country (2017-2028)
Figure 50. Mexico Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 51. Brazil Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 52. Argentina Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 53. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Company in 2021
Figure 54. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Type (2017-2028)
Figure 55. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Application (2017-2028)
Figure 56. Middle East and Africa Antisense and RNAi Therapeutics Revenue Share by Country (2017-2028)
Figure 57. Turkey Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 58. Saudi Arabia Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 59. UAE Antisense and RNAi Therapeutics Revenue (2017-2028) & (US$ Million)
Figure 60. Tekmira Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 61. Arbutus Biopharma Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 63. Antisense Therapeutics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 64. Silence Therapeutics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 65. Isis Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 66. Sirnaomics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 67. Santaris Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 68. Roche Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2017-2022)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
  • Global Targeted RNA Sequencing Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 71
    Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing The ability to detect both known and novel gene fusion partners in many sample types. In The report, we ......
  • Global Targeted RNA Sequencing Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 87
    According to our LPI (LP Information) latest study, the global Targeted RNA Sequencing market size was valued at US$ 1761.4 million in 2023. With growing demand in downstream market, the Targeted RNA Sequencing is forecast to a readjusted size of US$ 7649.2 million by 2030 with a CAGR of 23.3% during review period. The research report highlights the growth potential of the global Targeted RNA Sequencing market. Targeted RNA Sequencing are expected to show stable growth in the future mark......
  • Global Targeted RNA Sequencing Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 94
    According to our (Global Info Research) latest study, the global Targeted RNA Sequencing market size was valued at USD 1852.7 million in 2023 and is forecast to a readjusted size of USD 7255.4 million by 2030 with a CAGR of 21.5% during review period. Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or ......
  • Global Antisense and RNAi Therapeutics Market Research Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 2680 Onwards        Pages: 133
    Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (millio......
  • Global Antisense and RNAi Therapeutics Professional Survey Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 101
    Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (millio......
  • Global Targeted RNA Sequencing Market Research Report 2023, Forecast to 2028
    Published: 13-Nov-2023        Price: US 2680 Onwards        Pages: 137
    Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest.  Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......
  • Global Targeted RNA Sequencing Professional Survey Report 2023, Forecast to 2028
    Published: 13-Nov-2023        Price: US 3280 Onwards        Pages: 100
    Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest.  Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......
  • Global RNAi for Therapeutic Market Status and Outlook 2023-2028
    Published: 08-Nov-2023        Price: US 3160 Onwards        Pages: 106
    RNAi is a fundamental cellular mechanism for silencing gene expression that can be harnessed for the development of new drugs Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......
  • Global RNAi for Therapeutic Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 24-Oct-2023        Price: US 3380 Onwards        Pages: 104
    Market Overview of Global RNAi for Therapeutic market: According to our latest research, the global RNAi for Therapeutic market looks promising in the next 5 years. As of 2022, the global RNAi for Therapeutic market was estimated at USD 260.55 million, and it's anticipated to reach USD 3633.33 million in 2028, with a CAGR of 55.14% during the forecast years. RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs